NCT01758289终止不适用
A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis
AbbVie (prior sponsor, Abbott)8 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2013年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 105
- 试验地点
- 8
- 主要终点
- Percentage of Participants Achieving at Least a 30% Reduction From Baseline in the Levels of Parathyroid Hormone (PTH) at the Final Study Visit
研究概览
简要总结
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing secondary hyperparathyroidism associated with stage V chronic kidney disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years old with documented diagnosis of stage V chronic kidney disease, on hemodialysis at study baseline
- •Subjects who have been previously treated with vitamin D or its metabolites or naïve to paricalcitol
- •Subjects in whom the use of paricalcitol is clinically indicated and documented by applicable and routine standard of healthcare (i.e. laboratory assessments and clinical evaluations) according to the criteria of the attending physician and in accordance with the approved label of the product in Venezuela
- •Subjects that provide written informed consent form stating his/her authorization and willingness to participate in the study and allowing the use and discussion of his/her personal and/or health information before entering the study
- •Female subjects with reproductive potential must use an approved contraceptive method (intrauterine device, birth control pills or barrier device) during and for three (03) months after discontinuation of treatment
排除标准
- •Subjects with severe hyperparathyroidism (parathyroid hormone [PTH] > 3000 pg/mL)
- •Subjects with hypercalcemia, adjusted according to serum albumin, hyperphosphatemia, or subjects with calcium-phosphorus product (Ca x P) ≥ 70
- •Known hypersensitivity and/or toxicity of vitamin D, its metabolites and/or other components of Zemplar® IV (paricalcitol)
- •Subjects who have participated in clinical trials within 30 days before the start of the study or who are currently enrolled in a clinical trial or under treatment with any investigational product
- •Subjects who cannot tolerate or cannot take phosphate binders that do not contain calcium and/or aluminum
- •Subjects who in the opinion of the investigator, for any reason (including medical reasons) are not eligible and/or appropriate for therapy with synthetic analogs of vitamin D and/or unwilling to complete the study visits
结局指标
主要结局
Percentage of Participants Achieving at Least a 30% Reduction From Baseline in the Levels of Parathyroid Hormone (PTH) at the Final Study Visit
时间窗: Baseline Week 1 (Study Visit 1) to Week 24 (Final Study Visit)
次要结局
- European Quality of Life 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Scores At Baseline, Week 12, and Week 24(Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit))
- European Quality of Life 5 Dimensions (EQ-5D) Parameters of Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression At Baseline, Week 12, and Week 24(Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit))
- Number of Participants Achieving Parathyroid Hormone (PTH) Levels < 300 pg/mL(Baseline to Week 12, Week 12 to Week 24)
- Percentage of Participants With Hypercalcemia, Hyperphosphatemia and Elevations of Calcium-Phosphate Product (Ca x P) at Baseline, Week 12, and Week 24(Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit))
- Number of Participants Achieving PTH Level Reductions to < 300 pg/mL or 30% Below Baseline in 12 or 24 Weeks(Baseline Week 1 (Study Visit 1) to Week 24 (Final Study Visit))
- Beck Depression Inventory (BDI) Scores At Baseline and Final Study Visit(Baseline Week 1 (Study Visit 1), Week 24 (Final Study Visit))
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
ACTICOAT™ for the Treatment of Burns and Chronic WoundsWounds and InjuriesBurnsFoot UlcerPressure UlcerNCT02852148Smith & Nephew, Inc.25
已完成
不适用
Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With HemophiliaHemophiliaNCT06191068The Hospital for Sick Children190
已完成
不适用
An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With RituximabRheumatoid ArthritisNCT02507752Hoffmann-La Roche94
已完成
不适用
An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal AnemiaAnemiaNCT01105494Hoffmann-La Roche6,000
终止
不适用
Quality of Life and Pain Changes Due to DRG Stimulation for Chronic PainPelvic PainRegional Pain SyndromeChronic Pain SyndromeComplex Regional Pain SyndromesNerve Root, Pain SpinalNCT03417973KM Clinical Research Group55